Symptomatic hyponatraemia caused by cylophosphamide
Related Experiment Video
Updated: Jun 23, 2026

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
Anne Katrin Berger1, Frauke Bellos, Annika Siegmund
1Nationales Centrum fur Tumorerkrankungen, Universitatsklinikum Heidelberg, Im Neuenheimer Feld 350, Heidelberg, Germany.
Background:
Acute hyponatraemia after administration of alkylating agents such as cyclophosphamide or ifosfamide has been documented as an infrequent but life-threatening complication.
Case Report:
A 69-year-old female patient with metastatic adenocarcinoma of the salivary glands presented with severe symptomatic hyponatraemia (nadir 112 mmol/l) after chemotherapy with cyclophosphamide, cisplatin, and doxorubicin. Serum sodium was carefully corrected at the intensive care unit. The patient recovered completely from her neurological symptoms within a couple of days. A literature review showed only few cases with cyclophosphamide-induced acute hyponatraemia, and to our knowledge this is the first case where hyponatraemia was seen with a dose of only 500 mg/m(2) of cyclophosphamide.
Conclusion:
Oncologists should be aware of cyclophosphamide-induced acute hyponatraemia as a rare but life-threatening side-effect, especially since its clinical features may mimic those of chemotherapy-induced nausea.
Related Concept Videos
Cryptococcal Meningitis
Nephrotic Syndrome I : Introduction
Hemodialysis II: Procedure and Complications
Nephrotic Syndrome III : Nursing Management
Hyperosmolar Hyperglycemic State
Diabetes Insipidus II: Pathophysiology